{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kobel M"],"funding":["Cancer Council NSW","Fred C. and Katherine B. Andersen Foundation","Cancer Council Victoria","NCATS NIH HHS","Mayo Foundation for Medical Education and Research","Cancer Research UK","Cancer Council Tasmania","National Institutes of Health","University College London Hospitals Biomedical Research Centre","Canadian Institutes of Health Research","Institute of Cancer Research","Deutsches Krebsforschungszentrum","Peter MacCallum Foundation","Cancer Research Society","VGH and UBC Hospital Foundation","American Cancer Society","Instituto de Salud Carlos III","NIHR Cambridge Biomedical Research Centre","National Institute for Health Research (NIHR)","Cancer Institute NSW","Ministerio de Economía y Competitividad","Ovarian Cancer Australia","NIH HHS","University of Cambridge","National Center for Advancing Translational Sciences","Medical Research and Materiel Command","Breast Cancer Now","NCRR NIH HHS","Swedish Cancer Foundation","Minnesota Ovarian Cancer Alliance","Oak Foundation","Cancer Council South Australia","Sydney West Translational Cancer Research Centre","Biomedical Research Centre","Medical Research Council","U.S. Department of Defense","NCI NIH HHS","National Health and Medical Research Council","Pomorski Uniwersytet Medyczny W Szczecinie","European Regional Development Fund"],"pagination":["208-222"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10073933"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(3)"],"pubmed_abstract":["Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency o"],"journal":["The journal of pathology. Clinical research"],"pubmed_title":["p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study."],"pmcid":["PMC10073933"],"funding_grant_id":["628903","ID400281","UL1 TR001881","R01‐CA122443","R01 CA160669","12/RIG/1‐17","P30‐CA15083","SAF2012","U01 CA243483","N01‐CN‐55424","U01‐CA69417","PI 12/01319","UL1 TR000124","C490/A16561","ID400413","P50-CA136393","P50‐CA136393","15/RIG/1‐16","P30-CA15083","P50 CA136393","P30 CA015083","R01 CA087538","R01‐CA58598","19319","U01‐CA71966","R01-CA122443","K07 CA080668","MOP‐86727","P30 CA071789","N01 CA015083","R01 CA122443","R01 CA248288","15601","ID199600","CAN 2018/384","R01 CA058598","M01 RR000056","R01 CA095023","N01‐PC‐67001","R01 CA112523","UL1TR000124","22905","R01 CA243483","APP2009840","R01 CA168758","310670","R01‐CA243483","DAMD17‐01‐1‐0729","P30 CA047904","U01 CA069417","BRC‐1215‐20014","DAMD17‐02‐1‐0669","MC_UU_00004/01","SIOP‐06‐258‐01‐COUN","R01-CA243483"],"pubmed_authors":["Shah M","Kobel M","Sherman ME","Harnett PR","Sieh W","Boros J","Lubinski J","Gronwald H","Gronwald J","Alsop J","Gentry-Maharaj A","El-Bahrawy MA","Shvetsov YB","Jones ME","Longacre TA","Courtney-Brooks M","Lycke M","Staebler A","Kelemen LE","Orsulic S","Lester J","Fischer A","Modugno F","Koziak JM","Jimenez-Linan M","Hein A","Fortner RT","Karlan BY","Gayther SA","Meagher NS","Talhouk A","Benitez J","Sundfeldt K","Steed H","Hendley J","Ney B","Huntsman DG","Schildkraut JM","Cushing-Haugen KL","Candido Dos Reis FJ","Coulson P","Riggan MJ","Garcia MJ","Olawaiye A","Goodman MT","Wilkens LR","Bowtell DD","Lee CH","Huang Y","Deen S","Whittemore AS","McCauley BM","Grube M","Cybulski C","Erber R","Traficante N","Kennedy CJ","Wang C","Bisinotto C","Hartkopf AD","Pharoah PD","Winham SJ","Swerdlow AJ","Singh N","Barquin-Garcia A","Schoemaker MJ","Martin SG","Sharma R","Fereday S","Fasching PA","Rambau PF","Nelson GS","Widschwendter M","Carney ME","Hernandez BY","Brooks-Wilson A","Kluz T","Berchuck A","Le ND","Cook LS","Doherty JA","AOCS Group","Weir A","Storr SJ","Ghatage P","Ramon Y Cajal T","Menon U","Brand AH","Kommoss S","Mateoiu C","Beckmann MW","Lesnock J","Ramus SJ","Harris HR","DeFazio A","Osorio A","Paz-Ares L","McGuire V","Gilks CB","Hartmann A","Ruebner M","Brenton JD","Elishaev E","Campbell I","Kang EY","Anglesio MS","Rothstein JH","Jakubowska A","Boisen M","Goode EL"],"additional_accession":[]},"is_claimable":false,"name":"p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.","description":"Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency o","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-08-23T03:09:06.09Z","creation":"2025-04-06T11:28:18.957Z"},"accession":"S-EPMC10073933","cross_references":{"pubmed":["36948887"],"doi":["10.1002/cjp2.311"]}}